Compare ATEC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | IOVA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2006 | 2008 |
| Metric | ATEC | IOVA |
|---|---|---|
| Price | $8.24 | $4.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $22.00 | $9.00 |
| AVG Volume (30 Days) | 4.6M | ★ 13.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,739,000.00 | N/A |
| Revenue This Year | $18.97 | $47.74 |
| Revenue Next Year | $16.70 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.82 | $1.67 |
| 52 Week High | $23.29 | $5.63 |
| Indicator | ATEC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 61.90 |
| Support Level | $6.82 | $2.05 |
| Resistance Level | $16.58 | $4.27 |
| Average True Range (ATR) | 0.52 | 0.27 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 38.04 | 87.50 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.